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SUMMARY
A 29-year-old man presented with a 2-week history of
severe pain in the left foot with no preceding history of
trauma. A left foot radiograph demonstrated a cortical
lucency in the mid-distal shaft of the third metatarsal
bone. MRI of the left foot showed an expansile lesion in
the same location. A staging bone scan showed a focal
uptake in the known lucency in the left third metatarsal
and in the proximal left femur. A subsequent left hip
radiograph demonstrated a lucency in the
intertrochanteric region. CT scan of the chest, abdomen
and pelvis was unremarkable. A biopsy of the left third
metatarsal expansile lesion performed during an incision
and curettage procedure revealed an epithelioid
haemangioma (EHE) of the bone. MRI of the left hip
performed in response to the ﬁndings on the bone scan
showed metastatic disease in the left intertrochanteric
region. A prophylactic left hip ﬁxation surgery with an
interlocking intramedullary femoral nail was therefore
undertaken to avoid a pathological fracture of the left
hip from the metastatic disease. Simultaneously, a left
hip biopsy was performed, which also revealed an EHE.
The patient underwent external beam radiation to the
left femoral head and neck. This was followed by
fractionated radiosurgery to the left third metatarsal.
Once the left foot wound had healed, the patient
subsequently received four cycles of doxorubicin and
ifosfamide. A restaging positron emission tomography
CT carried out after completion of therapy showed no
metabolic evidence of residual primary tumour or
metastasis. More than 2 years after completing his
trimodality therapy, the patient remains fully functional
and symptom free.

BACKGROUND
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Primary vascular tumours of the bone represent a
heterogeneous group of neoplasms with a wide
spectrum of behaviours, ranging from benign to
malignant. Malignant vascular tumours are very
rare, representing less than 1% of primary malignant bone tumours. Over the years, there has been
signiﬁcant controversy surrounding the naming and
classiﬁcation of such tumours. In an effort to simplify and clarify the various vascular tumours, the
WHO classiﬁcation comprises four main groups:
haemangioma (benign), epithelioid haemangioma
(EHE) (locally aggressive), EHE (intermediate
grade) and angiosarcoma (malignant).1 2
EHE of the bone is an uncommon subtype of
these vascular tumours; it closely resembles an epithelial tumour, and may sometimes be mistaken for

a metastatic carcinoma. EHE affects only about one
person per million, worldwide, with nearly 20
cases diagnosed in the USA each year. Its treatment
can be challenging as there is currently no standard
therapy. Most of the experience is derived from
small case series and isolated case reports. We
present a case of EHE of the bone with classic
histological and immunophenotypic features, lowgrade cytomorphology and multifocal malignant
behaviour managed with a trimodality approach
including surgical excision followed by adjuvant
radiotherapy and chemotherapy.

CASE PRESENTATION
A 29-year-old man presented with a 2-week history
of severe pain in the left foot made worse by ambulation. It began spontaneously without preceding
trauma. The dorsal left mid-foot was tender to palpation, especially over the shaft of the third metatarsal bone. The patient also complained of a vague
left hip pain. The remainder of his medical, social
and family history was unremarkable.

INVESTIGATIONS
Left foot radiographs demonstrated an ill-deﬁned
cortical lucency in the mid-distal shaft of the third
metatarsal (ﬁgure 1).
A follow-up MRI of the left foot showed a
pathological fracture extending through a
4.3×1.5×1.3 cm expansile lesion within the middistal shaft of the left third metatarsal with surrounding soft tissue and bone marrow oedema
(ﬁgures 2 and 3).
Staging work up with a bone scan showed a focal
uptake in the known lucency in the left third metatarsal and in the proximal left femur (ﬁgure 4).
Left hip radiograph demonstrated a luceny in the
intertrochanteric region (ﬁgure 5).
CT scan of the chest, abdomen and pelvis
showed no evidence of visceral metastasis. An incisional biopsy with curettage of the primary lytic
lesion in the left third metatarsal shaft was then
undertaken. This conﬁrmed a low-grade EHE of
the bone. H&E staining of the left third metatarsal
biopsy revealed that the tumour in the metatarsal
was associated with organising haemorrhage and
bone spicules in the pathologic fracture. The
tumour was not overtly malignant, with barely any
mitoses or necrosis (ﬁgure 6).
The tumour was described by the pathologist as
having the typical immunophenotypic features of
this disease, including CD31 vascular marker
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Figure 1 Left foot radiographs showing a cortical lucency in the
mid-distal shaft of the third metatarsal bone.
positivity on sheets of hobnail type cells lining vascular spaces.
Immunostains for S100, keratins and CD1a were negative
(ﬁgure 7).
MRI of the left hip performed in response to the ﬁndings on
the bone scan showed multiple foci of signal abnormality within
the left femoral head and neck measuring up to 1.2 cm, worrisome
for metastatic disease in the left intertrochanteric region (ﬁgure 8).
The MRI of the left hip was carried out, despite the CT scan of
chest, abdomen and pelvis not being suggestive of metastatic
disease, to follow the radiological paradigm that a CT scan is not
as sensitive as an MRI in detecting and delineating the extent of a
suspected hip metastasis, which held true in our case. An MRI also
serves as a more useful guide for surgeons in preoperative planning
and to increase the yield of a biopsy specimen.

Figure 2 Left foot MRI showing an expansile lesion within the
mid-distal shaft of the left third metatarsal.
2

A prophylactic left hip ﬁxation surgery with an interlocking
intramedullary femoral nail was therefore undertaken to avoid a
pathological fracture of the left hip from metastatic disease.
Simultaneously, left hip bony reamings were obtained for
pathological examination. H&E staining of this left hip biopsy
showed that the tumour cells in the soft tissues and skeletal
muscles of the hip were epithelioid with minimal atypia or
mitoses, conﬁrming a diagnosis of EHE (ﬁgure 9).
Postoperative positron emission tomography (PET-CT)
showed moderate to intense ﬂuorodeoxyglucose (FDG) activity
in the region of the left femoral neck and intertrochanteric
region, suspicious for metastasis at the level of the recently
placed left femoral intertrochanteric screws. Mild FDG activity
within the left foot corresponding to known tumour involvement and resultant pathological fracture of the third metatarsal
were also noted (ﬁgure 10A, B left to right upper row).
Multiple foci of FDG activity within the soft tissues of the left
thigh and leg, the largest of which was located within the left
quadriceps femoris muscle, suggested metastatic disease. The
patient underwent a CT-guided biopsy of the FDG avid area in
the left biceps femoris muscle, which yielded only a haematoma
from postoperative bleeding, without evidence of malignancy.
We would like to bring to the reader’s attention here, that
additional vital information to our staging work up would have
been obtained by getting a pretreatment PET CT. However, the
PET CT was performed postoperatively due to delays in insurance approvals despite timely submission of PET CT requests
with the necessary supporting clinical documentation from our
end. We did not want to delay treatment until such approvals
went through. We did perform the PET CT once insurance
approvals went through postoperatively. We did this despite
knowing that we would have postoperative artefacts in the left
foot and left hip, because our purpose for this postoperative
PET CT was not as much to focus on the known disease sites
but rather to exclude other sites of critical but asymptomatic
multicentric disease such as spinal or intracranial disease that
may have existed, needing attention.
Postoperative radiographs of the left hip (ﬁgure 11) and left
foot (ﬁgure 12) showed an uncomplicated and unchanged
appearance of the left femoral intramedullary nail and fracture
union at the left third metatarsal shaft, respectively.
A second restaging PET CT, carried out 15 months after
therapy was completed, showed no evidence of residual tumour
in the left foot or left hip and no new disease elsewhere (ﬁgure
10C, D left to right lower row).
Saste A, et al. BMJ Case Rep 2015. doi:10.1136/bcr-2015-210196
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Figure 3 Left foot MRI showing an expansile lesion within the
mid-distal shaft of the left third metatarsal.
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DIFFERENTIAL DIAGNOSIS
▸
▸
▸
▸

Metastatic carcinoma
Chondromyxoid ﬁbroma
Epithelioid haemangioma
Epithelioid angiosarcoma

TREATMENT
Our patient, given his multifocal disease, was treated with a trimodality approach employing wide surgical excision followed
by adjuvant radiotherapy and chemotherapy.
An incisional biopsy with curettage of the primary lytic lesion
in the left third metatarsal shaft was carried out ﬁrst. The foot
was immobilised in a cast and kept non weight bearing, which
resulted in a complete union at the fracture site. The surgeons
did not deem a surgical ﬁxation necessary. The risk/beneﬁt ratio
favoured a conservative approach with immobilisation and
partial weight bearing.
Saste A, et al. BMJ Case Rep 2015. doi:10.1136/bcr-2015-210196

A prophylactic left hip ﬁxation with dynamic hip screws and
an interlocking intramedullary femoral nail was then undertaken
to avoid a pathological fracture of the left hip from metastatic
disease. During this procedure, bony reamings were obtained
for pathological examination.
The patient underwent external beam radiation, 50 Gy in 20
fractions, with a daily dose of 2.5 Gy to the left femoral head
and neck. The left third metatarsal primary site was treated by
fractionated radiosurgery with a total dose of 32 Gy, prescribed
to the 90% isodose line. The metastatic site of the left femoral
head was treated ﬁrst and the initial primary site of left third
metatarsal harbouring the pathological fracture was addressed
later. The two sites (femur and metatarsal) were not addressed
concurrently, so as to allow the left foot wound to heal completely before subjecting it to radiation. Additionally, given the
presence of a left foot plaster cast, radiating the left hip ﬁrst
made more clinical sense. The left hip metastasis, being much
3
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Figure 4 Bone scan showing focal
uptake in left third metatarsal and
proximal left femur.
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larger in size, with a potential to fracture from progressive
disease, warranted more immediate attention to avoid greater
long term disability from a potential pathological fracture.
The patient subsequently received four cycles of doxorubicin
and ifosfamide.

OUTCOME AND FOLLOW-UP
More

than 2 years after completing his trimodality therapy, the
patient remains fully functional in his profession as a police
ofﬁcer and is symptom free, with an Eastern Cooperative
Oncology Group (ECOG) performance status of zero. He
ambulates independently, and continues to be monitored with
serial imaging and clinical examinations.

DISCUSSION
Deﬁnition and classiﬁcation
Vascular tumours are tumours arising from the endothelial
linings of blood vessels. Nearly one half to two thirds originate
from a small vein.1 3
The WHO has classiﬁed vascular tumours of the bone as
follows:
1. Haemangioma (benign)
2. EHE (locally aggressive)
3. EHE (intermediate grade)
4. Angiosarcoma (malignant)

Figure 6 H&E staining of left third metatarsal biopsy showing
epithelioid cells with minimal atypia or mitoses.
4

Figure 7 Immunostaining showing CD31 positivity in epithelioid
tumour cells.

Synonyms
Intravascular bronchioloalveolar tumour, angioglomoid tumour,
myxoid angioblastomatosis.1

Incidence
EHE is a rare tumour. Its precise incidence is undetermined.1

Age/sex distribution
The lesion occurs in nearly all age groups with the exception of
early childhood years, and affects both sexes equally.1

Location
In descending order of frequency:4
1. Lower extremities: femur, tibia, ﬁbula and small bones of
feet—62%
2. Upper extremities: humerus, ulna, radius and small bones of
hands—14%
3. Vertebrae—10%
4. Concurrent parenchymal tumours—18%

Clinical features
EHE of the bone is a tumour that has a tendency to multicentricity.4 There is no clear distinction between multifocality and
metastatic disease. Some authors have described multifocal

Figure 8 Left hip MRI showing metastatic disease in the left
intertrochanteric region.
Saste A, et al. BMJ Case Rep 2015. doi:10.1136/bcr-2015-210196
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Figure 5 Left hip radiograph showing a lucency in the
intertrochanteric region.

Novel treatment (new drug/intervention; established drug/procedure in new situation)

disease as that which occurs in the same limb. Most of the
patients are asymptomatic at the time of the diagnosis but, if
symptomatic, pain appears to be a common theme across all
described reports. Pathological fractures and localised swelling
may also occur. Because these tumours arise from blood vessels
they may present with thrombophlebitis and extremity oedema.

Radiographic ﬁndings
CT scan and MRI show a well-demarcated osteolytic lesion with
no periosteal reaction. These usually remain conﬁned to bone
but may invade into surrounding soft tissue. A honeycomb-like
appearance with trabeculations can also be seen. Matrix mineralisation is uncommon.5

Immunohistochemistry and cytogenetics
EHE of the bone expresses a variety of endothelial antigenic
surface markers such as CD31, CD34 and FLI-1, which are
more reliable than von Willebrand factor.1
EHE can show cytokeratin positivity in 38% of cases and can
also focally express epithelial membrane antigen.2 8
Presence of translocations involving chromosome 1 and 3
[t (1; 3) ( p36.3; q25)], resulting in a wwtr1-camta1 fusion
product, is a consistent genetic abnormality of these tumors.1

Figure 10 Positron emission
tomography (PET-CT) showing
moderate to intense
ﬂuorodeoxyglucose (FDG) activity in
the left intertrochanteric region and
mild FDG activity within the left foot.
[A and B left to right upper row]. PET
CT showing resolution of FDG avidity
in left foot and left hip. [C and D left
to right lower row].
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Figure 9 H&E staining of left hip biopsy showing epithelioid cells
with minimal atypia or mitoses.

Bone scan may show doughnut-like lesions with increased
radiotracer uptake of the isotope.5
Unni et al described a positive correlation between the radiographic picture and the histological grade. Low-grade tumours
will show sharply demarcated margins and some bony trabeculae, whereas high-grade tumours have distinct and irregular
margins.3
EHE has a high incidence of multicentricity. A complete skeletal survey is therefore recommended.3
Treglia et al6 demonstrated the value of PET/MRI in the
diagnosis of FDG-avid multifocal bony and soft tissue EHE.
Davis et al7 also reported on the presence of FDG avid lesions
in their case report of a multifocal epithelioid sarcoma-like
haemangioendothelioma involving the cuboid and calcaneus
bones. These reports suggest that primary vascular tumours
show FDG avidity and, therefore, including a PET-CT or PET/
MRI as a part of the staging work up should remain a consideration. Given the multicentric tendency of these tumours,
PET-CT may aid in detection of occult disease in critical sites
such as the vertebral column, which may then warrant medical
intervention.

Novel treatment (new drug/intervention; established drug/procedure in new situation)

Figure 11 Radiographs of the left hip showing an uncomplicated
appearance of the left femoral intramedullary nail.

pathologists, case nurses and radiation oncologists, has resulted
in patients achieving the best outcomes.

Role of surgery
YAP1-TFE3 fusion has been noted in EHE, and these types
show a higher degree of vasoformation and solid tumour
growth, presence of TFE3 immunostaining and absence of the
more typical t(1:3) translocation.9

Pathology
Gross appearance: these tumours usually consist of soft red
nodular masses. The lesions can also be tan, solid and associated
with bony fragments, which may obscure the vascular nature of
the lesions.4

Histology
The histological hallmarks of EHE include nests and cords of
spindle-shaped eosinophilic endothelial cells referred to as
‘epithelioid or histiocytoid’, and intracytoplasmic vacuoles
(blister cells), myxoid/myxohyaline stroma and a low mitotic
count.4 A third of EHE show features suggesting malignant
potential such as marked nuclear atypia, high mitotic activity
(>1/hpf ), spindle cells and necrosis.1 Electron microscopy
shows neoplastic cells situated on a distinct basal lamina and
possessing surface-oriented pinocytic vesicles with occasional
Weibel-Palade bodies. They differ from normal endothelium by
the presence of numerous vimentin ﬁlaments.

Treatment
In our experience, multidisciplinary involvement with tumour
board discussions involving oncosurgeons, medical oncologists,
6

The mainstay of treatment is complete surgical resection of
the tumour with the aim to achieve negative margins. A wide
local excision is recommended even for a low-grade tumour,
since these can also act aggressively and have the ability to
metastasise. Additionally, if the biopsy specimen is not
representative of the entire tumour, the patient may be
undertreated.10
Luzzati et al11 proposed that wide local excision with negative
margins is probably associated with a more favourable long term
disease control and survival as compared to surgeries with positive margins or lesions treated with chemotherapy and radiation
alone.

Role of radiofrequency ablation
Rosenthal et al12 report that using radiofrequency ablation
(RFA) as an adjunctive procedure can limit the requirement for
surgery where wide resection would result in signiﬁcant functional or cosmetic deﬁcits. Davis et al7 have reported on their
successful use of RFA for multicentric bony epithelioid sarcomas, including haemangioendotheliomas, yielding a disease free
survival (DFS) of 2 years at the time of publication.

Role of radiation and chemotherapy
Adjuvant chemotherapy and radiation have been used in combination when surgical margins are positive or when surgery is
not an option due to multicentric involvement or locally
advanced disease.13
Saste A, et al. BMJ Case Rep 2015. doi:10.1136/bcr-2015-210196
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Figure 12 Radiographs of the left foot showing fracture union of the
left third metatarsal shaft.

Novel treatment (new drug/intervention; established drug/procedure in new situation)
A deﬁnitive radiation dose for bony EHE has not been well
studied. Intensity modulated radiation therapy (IMRT) has been
used to avoid radiation exposure to normal surrounding
tissues.14 Drazin et al13 used an adjuvant dose of 33 fractions of
a total dose of 5940 cGy for a mastoid EHE with 8-year disease
free survival. Yim et al15 used a dose of 55 Gy in 32 fractions
over 43 days to achieve remission for an unresectable cervical
EHE. In their case report, EHE was reported to be sensitive to a
radiation dose of 30–40 Gy. Gherman et al16 used an adjuvant
radiation dose of 60 Gy in 23 fractions for an EHE of the
radius status postresection with negative margins. Angelini
et al,17 in their case series of 62 bony EHE, reported that, given
the risk of radiation-induced sarcomas, radiation therapy should
be utilised only in situations where wide surgery with negative
margins cannot be obtained or when lesions are difﬁcult to
access surgically due to their location.

Patient’s perspective
When I was diagnosed with epithelioid haemangioma (EHE),
I did not know what to expect. I know that the cancer can
come back anytime so that is why I feel scared. Now the pain
in my foot is very tolerable and that makes me feel safe. I feel
safe in your hands as doctors. I thought chemotherapy was
harsh on me. I was on very strong medications, which 5 days
after still made me sick with nausea, vomiting, anxiety and hair
loss. However, that was totally worth it because I am alive. I am
very glad it was caught early; and the fact that you are telling
PEOPLE ABOUT this CONDITION IS great.

Learning points
Chemotherapy
Kleer et al5 reported, in his series of 40 cases from the Mayo
Clinic, that the efﬁcacy of adjuvant chemotherapy cannot be
proven as too few patient have received this treatment modality.
Chemotherapy has been used adjuvantly to treat tumours
involving multiple bones or parenchymal organs.5
Carboplatin and paclitaxel in combination with bevacizumab
for its vascular endothelial growth factor (VEGF) targeting
properties have shown some success in bony EHE.18 Another
regimen used in multifocal tumours is six cycles of epirubicin
and ifofosfamide, plus two cycles of etoposide.17 A combination
of doxorubicin and isosfamide has proved to be active in
advanced soft tissue sarcomas as well and has been widely
used.18
Thalidomide and, less frequently, lenalidomide, have been
tried due to their antiangiogenic properties. Interferon α with
its antiangiogenic properties has also shown activity in EHE.19
Because EHE expresses VEGF receptors, sorafenib, a small
molecule BRAF and VEGF receptor inhibitor, is a logical candidate for the treatment of EHE. Chevreau et al20 studied 15
patients, who were not candidates for curative surgery and
radiotherapy, who received sorafenib. The 9-month progressionfree rate was 30.7% (4 of 13 patients). No complete responses
were observed.
Bally O et al have reported on a patient with liver and lung
EHE whose disease responded to pazopanib with an 8-year progression free survival (PFS), which is unheard of in other
sarcoma subtypes where the median PFS is about 4.5 months
with this medication. This patient had progressed on prior therapies, including doxorubicin and brostacilline. Pazopanib is the
only VEGF inhibitor approved for sarcomas. The 5-year survival
rate after conventional chemotherapy is less than 30% in
sarcomas.21

▸ Epithelioid haemangioendothelioma of the bone is a rare
vascular tumour arising from the endothelial lining; it can be
locally aggressive and have a tendency towards
multicentricity.
▸ The prognosis will depend on the extent of disease and can
be favourable, even with metastatic disease, with timely
diagnosis and treatment involving a multidisciplinary team
of surgeons, and medical and radiation oncologists.
▸ Wide local excision with negative margins has the highest
chances of yielding a cure. Positive margins, unresectable or
multicentric disease beneﬁts from adjuvant radiation and
chemotherapy.
▸ A treatment plan based on tumour board discussions
improves ﬁnal outcomes for the patient.
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